Abstract:Potential conflict of interest: Nothing to report. Author names in bold denote shared co‐first authorship. To the Editor: We read with interest the article by Suh et al.,1 in which they highlighted that elevated FIB‐4 significantly increased hepatocellular carcinoma (HCC) incidence among hepatitis B surface antigen carriers. Coincidentally, Chon and colleagues showed a middle accuracy of FIB‐4 in predicting HCC development among patients with chronic hepatitis B.2 As we know, FIB‐4 was generally identified as a screening tool for hepatic fibrosis and cirrhosis in chronic hepatitis B patients.3 Given that liver cirrhosis has been defined as an independent predictor of poor survival in hepatitis B–associated HCC,4 it is necessary to investigate whether or not FIB‐4 could also predict survival in these patients. Recently, we conducted a retrospective cohort study and demonstrated that several cirrhosis‐related noninvasive models, including FIB‐4, were valuable for predicting survival in HCC patients without distinguishing hepatitis B from other causes.5 To further evaluate the prognostic significance of FIB‐4 in hepatitis B–associated HCC, herein we involved 324 hepatitis B surface antigen–positive HCC patients. After a median follow‐up period of 44 months, 204 patients died and 148 patients had recurrence. The receiver operating characteristic curve showed an optimal cutoff value of 4.33 for FIB‐4 in predicting postoperative death, with 52.5% sensitivity and 71.7% specificity. A log‐rank test showed that FIB‐4 was significantly associated with overall survival (Fig. 1A) and disease‐free survival (Fig. 1B). The 1‐, 3‐, and 5‐year cumulative overall survival rates were 66.9%, 51.2%, and 42.1%, respectively, for the 183 patients with FIB‐4 <4.33 compared with 50.0%, 28.0%, and 17.2%, respectively, for the 141 patients with a high level. Furthermore, multivariate analysis revealed that FIB‐4 was an independent prognostic factor for overall survival (hazard ratio = 1.47, 95% confidence interval 1.04‐2.08, P = 0.029) and disease‐free survival (hazard ratio = 1.45, 95% confidence interval 1.02‐2.04, P = 0.037) after adjustment for gender, age, Child‐Pugh stage, alpha‐fetoprotein, tumor size, tumor number, and therapeutic method.Figure 1: Kaplan‐Meier survival curves of our study population. Overall survival (A) and disease‐free survival (B) of hepatocellular carcinoma patients stratified according to FIB‐4 levels.In conclusion, FIB‐4 is not only a valuable predictor for cirrhosis and HCC incidence among chronic hepatitis B patients but also significant for predicting postoperative survival in hepatitis B–related HCC.

Usefulness of the Fibrosis-4 Index and Alanine Aminotransferase at 1 Year of Nucleos(t)ide Analog Treatment for Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

The Diagnostic Value of the Fib-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis

One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment

Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study

High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs

Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy

Prognostic Value of Non-Invasive Fibrosis Indices Post-Curative Resection in Hepatitis-B-associated Hepatocellular Carcinoma Patients

Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients

Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study

Hepatocellular Carcinoma Progression in Hepatitis B Virus-Related Cirrhosis Patients Receiving Nucleoside (acid) Analogs Therapy: A Retrospective Cross-Sectional Study.

Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years after SVR.

Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD

FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study

Role of early on-treatment serum HBV RNA declines in predicting hepatocellular carcinoma risk in patients with chronic hepatitis B

Interferon-based Treatment is Superior to Nucleos(t)ide Analog in Reducing HBV-related Hepatocellular Carcinoma for Chronic Hepatitis B Patients at High Risk

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Predictive Value of Alpha-Fetoprotein in the Long-Term Risk of Developing Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection--results from a Clinic-Based Longitudinal Cohort.

The effects of nucleos(t)ide analogues treatment on prognosis of patients with chronic hepatitis B - related hepatocellular carcinoma

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD

FIB‐4 As a Prognostic Model for Patients with Hepatitis B–associated Hepatocellular Carcinoma

Risk factors of hepatocellular carcinoma in patients with HBV-related liver cirrhosis receiving nucleos (t) ide analogues treatment